The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001179325p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
3/09/2026
Date registered
Help: Date registered
22/09/2026
Date last updated
Help: Date last updated
22/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/09/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Positive Behaviour Support for Major Neurocognitive Disorder in the Aotearoa Context: Optimising Quality of Life
Scientific title
Positive Behaviour Support for Major Neurocognitive Disorder in the Aotearoa Context: Evaluating the impact on behavioural indices of mood and distress
Additional trial identifiers [1] 318350 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
major neurocognitive disorder 343478 0
Condition category
Condition code
Neurological 339579 339579 0 0
Dementias
Neurological 339580 339580 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Observational data: The study will begin with a stage of data collection, associated with baseline (or initial) information gathering. This will involve researchers observing (watching) the behaviours of consented participants (individuals with major neurocognitive disorder (NCD) and/or care or support people) and recording behaviours (e.g., indices of affect, engagement, vocal verbal responses) using pen and paper methods or unobtrusive technology (i.e., through the use of an iPad or similar) at various times. No specific actions will be required of participants at this stage. Baseline observational data will be collected during 10 to 20-minute periods at different times of the day across a between one and four weeks to capture the majority of behaviours etc. The overall duration of participation for people diagnosed with major neurocognitive disorder and their whanau/ family members in this phase will be between two weeks and two months.

Assessment (1): This stage will involve gathering information by asking informants (participants who support an individual with NCD, including whanau and/or staff who are consented to participate in the study) to comment on events and their perceptions of events. This will be achieved through a short (no longer than 20 minutes) interview (modality may vary depending on the preference of the research team and participants, i.e., online, in person, pen and paper survey). This will be achieved through a short (no longer than 30 minutes) interview (modality may vary depending on the preference of the research team and participants, i.e., online, in person, pen and paper survey). The predicted number of sessions is between 3 and 10 per participant. The total number of sessions and duration of sessions will vary participant-by-participant based on observation of participant behaviour, e.g., attention, fatigue, mood changes and practical factors such as availability, scheduling etc. The overall duration of participation for people diagnosed with major neurocognitive disorder and their whanau/ family members in this phase will be between two weeks and one month.

Assessment (2): This stage will involve brief assessment activities where the research team modifies the environmental stimuli (e.g., such as adding access to attention, or activities) for the individuals with NCD, and measure any change to behaviours of interest before and after the modification. The assessments will comprise multiple sessions lasting no longer that 30 minutes, and have structured protocols and session termination criteria to protect participants and researchers. This phase will occur after the completion of Assessment 1. The overall duration of participation for people diagnosed with major neurocognitive disorder and their whanau/ family members in this phase will be between two weeks and two months.

Intervention (1): This element of the research will involve using information (gathered using methods listed above) and the researchers' clinical judgement to identify likely effective and best-practice intervention approaches that are matched to the reasons for distress behaviours and are minimally intrusive/promote quality of life. This stage will involve working with individuals with NCD. These interventions will be yoked to data analysis, and so cannot be explicitly stated at this stage of the project, but may include: redirecting, teaching participants skills to help carers recognise their distress, enriching the participant's lived environment, providing participants with choice of activities, and other empirically-supported evidence based treatments common in behaviour analytic intervention. Data collection through observation will continue at this stage. A researcher will interact with an individual participant in a shared space where other participants may be present, or in private quarters (depending on the change to be implemented). Sessions will be between 10 and 30-min in duration, implemented up to five times per week for up to 2 months. This stage will be implemented upon completion of the assessment phases.

The changes implemented will be selected by the CI, using their clinical judgement and the data collected in Assessment 1 and 2 (i.e., based on participant preferences, mobility, any medical contraindications, feasibility, available resource). Proposed changes will be presented to the organisation for their approval prior to implementation and to provide an additional check for safety and feasibility (for example, we will not suggest a change in location for cares for a participant whose mobility would make it unsafe to move them to another room in the space). The changes will be implemented by the CI (registered psychologist), supporting staff (e.g., occupational therapists, rehabilitation assistants), and other members of the research team. A researcher will interact with an individual participant in a shared space where other participants may be present, or in private quarters (depending on the change to be implemented). Sessions will be between 10 and 20-min in duration, implemented up to five times per week for up to 2 months. This stage will be implemented upon completion of the assessment phases. The overall duration of participation for people diagnosed with major neurocognitive disorder and their whanau/ family members in this phase will be between two weeks and two months.

Intervention (2): This step of the study involves teaching and supporting consented care and support staff to modify the approaches they use when interacting with individuals they support, to reduce distress and increase behaviours that promote quality of life. Again, the specific intervention technologies will be tied to baseline data and specific to each participant. The teaching methods may include the use of behavioural skills training (such as didactic instruction, modelling, rehearsal and feedback, face-to-face with practical examples in care situations). A member of the research team will conduct the teaching sessions and deliver the training to care staff. Data will be collected at this stage through observation of consented participant behaviour (that of care support people and individuals with NCD). Teaching sessions will be between 10 and 30-min in duration, implemented up to five times per week for up to 2 months. People with major neurocognitive disorder will be involved in between 10 and 20 sessions of up of 30-min in duration for in-situ training. Their whanau will be involved in between 10 and 20 sessions of up to 30-min in duration to be able to provide feedback. This stage will be implemented upon completion of Intervention 1. The overall duration of participation for people diagnosed with major neurocognitive disorder and their whanau/ family members in this phase will be between two weeks and one month.

The perspectives and opinions of consented whanau, and caregivers / support people will be recorded using informant methods (as described in Assessment: 1). Care will be taken to minimise the response time and effort required for this task. Consented individuals with NCD may also be asked to provide their perspectives of participation through a modified tool, aligned with the cognitive skills of participants and in line with participant preference.

A second observer will be present in approximately 30% of sessions to record treatment integrity data.

The changes implemented will only be made for the individual participant (i.e., not others in the organisation). Some examples are:

Participants are given structured choices in how their care is delivered.
Participants are taught skills to alert carers that they are uncomfortable.
Changes to the physical spaces, activities, or materials are made.
Sensory stimuli are presented or adapted.
Schedules of check-ins and social interactions with carers are added.
Intervention code [1] 335242 0
Behaviour
Description of the comparator or control
Across stages of the project, single-subject design (i.e., small-n design) will be used. This approach involves measuring the behaviour of participants at various stages of the research / within various phases, to assess any change by comparing that participant's data with a record of their baseline performance (otherwise described as 'subject as their own control').
Control group
Active

Outcomes
Primary outcome [1] 346758 0
Indices of affect (including facial expression, vocalisations, body language). Behaviours to be operationally defined for each participant- composite outcome.
Timepoint [1] 346758 0
Repeated measures - data collected in every baseline, functional assessment, and intervention session that occurs for 6 months from enrolment.
Primary outcome [2] 346759 0
Engagement - operationally defined for each participant with regard to objective descriptions of what they do and / or say.
Timepoint [2] 346759 0
Repeated measures - data collected in every baseline, functional assessment, and intervention session that occurs for 6 months from enrolment.
Primary outcome [3] 346760 0
Distress - operationally defined for each participant with regard to objective descriptions of what they do and / or say.
Timepoint [3] 346760 0
Repeated measures - data collected in every baseline, functional assessment, and intervention session that occurs for 6 months from enrolment.
Secondary outcome [1] 467365 0
Acceptability of assessment and intervention (participant) - composite outcome
Timepoint [1] 467365 0
At the time of enrolment, after assessment phases, and after the last intervention session.
Secondary outcome [2] 467366 0
Acceptability of assessment and intervention (whanau or professional carer) - composite outcome
Timepoint [2] 467366 0
At the time of enrolment, after assessment phases, and after the last intervention session.
Secondary outcome [3] 467367 0
Staff competence in implementing strategies - operationally defined for each participant with regard to objective descriptions of what they do and / or say.
Timepoint [3] 467367 0
Repeated measures - data collected in every session that occurs for 6 months from enrolment.

Eligibility
Key inclusion criteria
Group 1: People diagnosed with major neurocognitive disorder prior to participating in the study (i.e., have an existing, independent diagnosis) who engage in distress behaviour.
Group 2. Whanau/ family members of participants with NCD.
Group 3. Professional caregivers or support staff members who provide care to participants with NCD.

.We do not have an inclusion criterion for age, as we wish to include individuals with, for example, young-onset dementia because this is likely to be beneficial for these groups and future research. However, participants must be over 16 years old in order to be included as a legal adult in NZ.

We also do not have a criterion for specific diagnosis (e.g., type of dementia or mechanism of brain injury). We are not seeking to make broad generalisations about people with a specific diagnosis, but start to understand some of the factors that should be considered in understanding and intervening upon distress. As such, and due to our small-N design approach, we are not seeking an homogenous sample.
Minimum age
16 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
People who are unable to provide consent on their own behalf and for whom there is no one who carries Protection of Personal Property Rights (PPPR) to consent to their involvement. Proxy consent from a legal proxy will only be sought when participation is in the best interests of the person (in accordance with the National Ethics Advisory Committee NEAC standards 7.70 - 7.75).

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment outside Australia
Country [1] 28495 0
United States of America
State/province [1] 28495 0
Country [2] 28561 0
New Zealand
State/province [2] 28561 0

Funding & Sponsors
Funding source category [1] 322910 0
University
Name [1] 322910 0
University of Auckland
Country [1] 322910 0
New Zealand
Primary sponsor type
University
Name
University of Auckland
Address
Country
New Zealand
Secondary sponsor category [1] 325833 0
University
Name [1] 325833 0
University of North Texas
Address [1] 325833 0
Country [1] 325833 0
United States of America
Secondary sponsor category [2] 325835 0
University
Name [2] 325835 0
University of Western Michigan
Address [2] 325835 0
Country [2] 325835 0
United States of America

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 321336 0
Northern B Health and Disability Ethics Committee 
Ethics committee address [1] 321336 0
Ethics committee country [1] 321336 0
New Zealand
Date submitted for ethics approval [1] 321336 0
30/09/2026
Approval date [1] 321336 0
Ethics approval number [1] 321336 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153406 0
Dr Rebecca Sharp
Address 153406 0
Science Centre, Symonds Street, 1010, Auckland, The University of Auckland
Country 153406 0
New Zealand
Phone 153406 0
+64 9 923 2073
Fax 153406 0
Email 153406 0
Contact person for public queries
Name 153407 0
Rebecca Sharp
Address 153407 0
Science Centre, Symonds Street, 1010, Auckland, The University of Auckland
Country 153407 0
New Zealand
Phone 153407 0
+64 9 923 2073
Fax 153407 0
Email 153407 0
Contact person for scientific queries
Name 153408 0
Rebecca Sharp
Address 153408 0
Science Centre, Symonds Street, 1010, Auckland, The University of Auckland
Country 153408 0
New Zealand
Phone 153408 0
+64 9 923 2073
Fax 153408 0
Email 153408 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.